Free tool
FAERS Monitor: Xopenex Hfa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021730 or its brand name (Xopenex Hfa, Levalbuterol Tartrate). Reports on generic versions are filed under their own applications.
Reports
3,733
Serious
1,628
44% of reports
Hospitalization
783
Death reported
129
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- device delivery system issue642
- drug dose omission by device556
- no adverse event510
- dyspnoea440
- headache244
- nausea229
- fatigue225
- cough213
- asthma210
- off label use197
- dizziness174
- pneumonia172
- drug ineffective166
- diarrhoea153
- sinusitis152
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 7 |
| 2007 | 24 |
| 2008 | 45 |
| 2009 | 33 |
| 2010 | 28 |
| 2011 | 42 |
| 2012 | 78 |
| 2013 | 78 |
| 2014 | 92 |
| 2015 | 141 |
| 2016 | 294 |
| 2017 | 190 |
| 2018 | 167 |
| 2019 | 190 |
| 2020 | 210 |
| 2021 | 145 |
| 2022 | 178 |
| 2023 | 358 |
| 2024 | 471 |
| 2025 | 545 |
| 2026 | 417 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,426 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device delivery system issueSignal | 642 | 135.3 | 125.9 | 83,534 |
| drug dose omission by deviceSignal | 556 | 40.3 | 37.3 | 21,189 |
| no adverse eventSignal | 510 | 15.9 | 14.7 | 7,148 |
| asthmaSignal | 210 | 10.5 | 9.2 | 1,799 |
| sinusitisSignal | 152 | 8.4 | 7.2 | 982 |
| dyspnoeaSignal | 440 | 4.4 | 4.0 | 1,176 |
| coughSignal | 213 | 4.3 | 3.8 | 539 |
| pneumoniaSignal | 172 | 3.0 | 2.6 | 230 |
| headacheSignal | 244 | 2.2 | 1.9 | 162 |
| dizziness | 174 | 2.0 | 1.7 | 84 |
| nausea | 229 | 1.6 | 1.4 | 57 |
| fatigue | 225 | 1.6 | 1.4 | 56 |
| diarrhoea | 153 | 1.3 | 1.1 | 13 |
| off label use | 197 | 1.3 | 1.1 | 11 |
| drug ineffective | 166 | 0.7 | 0.6 | 21 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.